Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Cabaletta Bio, Inc.NASDAQ: CABA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$43.52M, compared with -$35.94M a year earlier. Trailing-twelve-month net income was -$175.43M.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$133.66M (+20.4%) for the fiscal year ending Dec 2026, a step up from the -44.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43.52M-3.8% QoQ
Last fiscal yearDec 2025
-$167.86M-44.9% YoY
LTMMar 2026
-$175.43M-38.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.1%+7.4%+28.5 pp
1 year-44.9%+20.4%+65.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(167.86M) USD
Year-over-year change
-44.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.4% is the 8th highest of 11, against a peer median of -14.5%.
CABA Competitors
Net Income for CABA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.62M EUR-51.2%—339.4%
IMMPImmutep LimitedFY2025-A$61.43M AUD-43.8%—1218.0%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$87.5M USD+19.9%——
HUMAHumacyte, Inc.LTM Mar 2026-$97.59M USD-25.7%—4840.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$114.59M USD-108.1%——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$156.4M USD-7.6%——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$169.52M USD-21.5%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.1%——
CABACabaletta Bio, Inc.LTM Mar 2026-$175.43M USD-38.4%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
Peer median (excluding CABA) —-14.5%—1218.0%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.49M39.3M55.42M97.2M142.67M
Selling, General & Admin13.82M14.84M19.24M27.94M29.57M
Operating Expenses46.31M54.14M74.66M125.14M172.24M
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
EBITDA(45.56M)(51.8M)(66.25M)(113.41M)(164.21M)
EBITDA Margin—————
Operating Income(46.31M)(54.14M)(74.66M)(125.14M)(172.24M)
Operating Margin—————
Interest Income24K1.16M6.99M10.03M6.03M
Interest Expense000748K2M
Other Income / Expenses24K1.16M6.99M9.28M4.39M
Income Before Tax(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Net Margin—————
EPS (Basic)(1.80)(1.81)(1.65)(2.34)(1.64)
EPS (Diluted)(1.80)(1.81)(1.65)(2.34)(1.64)
Weighted Avg Shares25.74M29.34M40.95M49.52M102.26M
Weighted Avg Shares (Diluted)25.74M29.34M40.95M49.47M102.26M

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.